Xanthomonas (Stenotrophomonas) maltophilia
Jump to navigation
Jump to search
Pathology
- commonly causes nosocomial infections.
Pharmacology
- resistant to:
- generally susceptible to:
Laboratory
- Stenotrophomonas maltophilia DNA[2]
- culture
- glucose oxidizer; lysine decarboxylase +
- pigment yellow; motility +; MacConkey +
- cytochrome-oxidase -
Management
- in order of preference[4]
- cefiderocol (with a second agent)
- ceftazidime-avibactam & aztreonam
- aztreonam-avibactam[5]
- minocycline (with a second agent)
- trimethoprim-sulfamethoxazole (with a second agent)
- levofloxacin (with a second agent)
- tigecycline is no longer listed as a component of combination therapy[4]
More general terms
References
- ↑ Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 499
- ↑ 2.0 2.1 Loinc
- ↑ 3.0 3.1 Medical Knowledge Self Assessment Program (MKSAP) 18, American College of Physicians, Philadelphia 2018
- ↑ 4.0 4.1 4.2 Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024 Aug 7:ciae403. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39108079 https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciae403/7728556
- ↑ 5.0 5.1 Carmeli Y et al. Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): A descriptive, multinational, open-label, phase 3, randomised trial. Lancet Infect Dis 2025 Feb; 25:218 PMID: https://www.ncbi.nlm.nih.gov/pubmed/39389071